233 related articles for article (PubMed ID: 22421195)
1. Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial.
DuBois SG; Chesler L; Groshen S; Hawkins R; Goodarzian F; Shimada H; Yanik G; Tagen M; Stewart C; Mosse YP; Maris JM; Tsao-Wei D; Marachelian A; Villablanca JG; Matthay KK
Clin Cancer Res; 2012 May; 18(9):2679-86. PubMed ID: 22421195
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma.
DuBois SG; Allen S; Bent M; Hilton JF; Hollinger F; Hawkins R; Courtier J; Mosse YP; Matthay KK
Br J Cancer; 2015 Feb; 112(4):644-9. PubMed ID: 25602966
[TBL] [Abstract][Full Text] [Related]
3. Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium.
DuBois SG; Granger MM; Groshen S; Tsao-Wei D; Ji L; Shamirian A; Czarnecki S; Goodarzian F; Berkovich R; Shimada H; Villablanca JG; Vo KT; Pinto N; Mosse YP; Maris JM; Shusterman S; Cohn SL; Goldsmith KC; Weiss B; Yanik GA; Twist CJ; Irwin MS; Haas-Kogan DA; Park JR; Marachelian A; Matthay KK
J Clin Oncol; 2021 Nov; 39(31):3506-3514. PubMed ID: 34270348
[TBL] [Abstract][Full Text] [Related]
4. Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma.
DuBois SG; Groshen S; Park JR; Haas-Kogan DA; Yang X; Geier E; Chen E; Giacomini K; Weiss B; Cohn SL; Granger MM; Yanik GA; Hawkins R; Courtier J; Jackson H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Villablanca JG; Marachelian A; Matthay KK
Clin Cancer Res; 2015 Jun; 21(12):2715-21. PubMed ID: 25695691
[TBL] [Abstract][Full Text] [Related]
5. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma.
Mody R; Zhao L; Yanik GA; Opipari V
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28436582
[TBL] [Abstract][Full Text] [Related]
8. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
DuBois SG; Marachelian A; Fox E; Kudgus RA; Reid JM; Groshen S; Malvar J; Bagatell R; Wagner L; Maris JM; Hawkins R; Courtier J; Lai H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Matthay KK; Mosse YP
J Clin Oncol; 2016 Apr; 34(12):1368-75. PubMed ID: 26884555
[TBL] [Abstract][Full Text] [Related]
9. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma.
Matthay KK; DeSantes K; Hasegawa B; Huberty J; Hattner RS; Ablin A; Reynolds CP; Seeger RC; Weinberg VK; Price D
J Clin Oncol; 1998 Jan; 16(1):229-36. PubMed ID: 9440747
[TBL] [Abstract][Full Text] [Related]
10. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.
Matthay KK; Tan JC; Villablanca JG; Yanik GA; Veatch J; Franc B; Twomey E; Horn B; Reynolds CP; Groshen S; Seeger RC; Maris JM
J Clin Oncol; 2006 Jan; 24(3):500-6. PubMed ID: 16421427
[TBL] [Abstract][Full Text] [Related]
11. Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors.
McNall-Knapp RY; Williams CN; Reeves EN; Heideman RL; Meyer WH
Pediatr Blood Cancer; 2010 Jul; 54(7):909-15. PubMed ID: 20405511
[TBL] [Abstract][Full Text] [Related]
12. Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy.
Mastrangelo S; Tornesello A; Diociaiuti L; Pession A; Prete A; Rufini V; Troncone L; Mastrangelo R
Br J Cancer; 2001 Feb; 84(4):460-4. PubMed ID: 11207038
[TBL] [Abstract][Full Text] [Related]
13. 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study.
Yanik GA; Villablanca JG; Maris JM; Weiss B; Groshen S; Marachelian A; Park JR; Tsao-Wei D; Hawkins R; Shulkin BL; Jackson H; Goodarzian F; Shimada H; Courtier J; Hutchinson R; Haas-Koga D; Hasenauer CB; Czarnecki S; Katzenstein HM; Matthay KK
Biol Blood Marrow Transplant; 2015 Apr; 21(4):673-81. PubMed ID: 25639769
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.
Wagner LM; Perentesis JP; Reid JM; Ames MM; Safgren SL; Nelson MD; Ingle AM; Blaney SM; Adamson PC
Pediatr Blood Cancer; 2010 Apr; 54(4):538-45. PubMed ID: 20049936
[TBL] [Abstract][Full Text] [Related]
15. Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study.
Matthay KK; Quach A; Huberty J; Franc BL; Hawkins RA; Jackson H; Groshen S; Shusterman S; Yanik G; Veatch J; Brophy P; Villablanca JG; Maris JM
J Clin Oncol; 2009 Mar; 27(7):1020-5. PubMed ID: 19171714
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors.
Mascarenhas L; Ogawa C; Laetsch TW; Weigel BJ; Bishop MW; Krystal J; Borinstein SC; Slotkin EK; Muscal JA; Hingorani P; Levy DE; Mo G; Shahir A; Wright J; DuBois SG
Cancer Med; 2021 Feb; 10(3):843-856. PubMed ID: 33474828
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study.
Bagatell R; London WB; Wagner LM; Voss SD; Stewart CF; Maris JM; Kretschmar C; Cohn SL
J Clin Oncol; 2011 Jan; 29(2):208-13. PubMed ID: 21115869
[TBL] [Abstract][Full Text] [Related]
18. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma.
DuBois SG; Messina J; Maris JM; Huberty J; Glidden DV; Veatch J; Charron M; Hawkins R; Matthay KK
J Clin Oncol; 2004 Jun; 22(12):2452-60. PubMed ID: 15197208
[TBL] [Abstract][Full Text] [Related]
19. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.
French S; DuBois SG; Horn B; Granger M; Hawkins R; Pass A; Plummer E; Matthay K
Pediatr Blood Cancer; 2013 May; 60(5):879-84. PubMed ID: 23024113
[TBL] [Abstract][Full Text] [Related]
20. Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312).
Cole KA; Pal S; Kudgus RA; Ijaz H; Liu X; Minard CG; Pawel BR; Maris JM; Haas-Kogan DA; Voss SD; Berg SL; Reid JM; Fox E; Weigel BJ
Clin Cancer Res; 2020 Mar; 26(6):1213-1219. PubMed ID: 31857431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]